Advance Search
LU Tao, ZUO Junli. Effect of roxithromycin combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease patients complicating with pulmonary interstitial fibrosis[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 72-76. DOI: 10.7619/jcmp.202010018
Citation: LU Tao, ZUO Junli. Effect of roxithromycin combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease patients complicating with pulmonary interstitial fibrosis[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 72-76. DOI: 10.7619/jcmp.202010018
shu

Effect of roxithromycin combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease patients complicating with pulmonary interstitial fibrosis

  • 1. Department of Pharmacy, Shangnan County Hospital, Shangluo, Shaanxi, 726300;

  • 2. Department of Respiratory and Critical Care Medicine, Xi'an International Medical Center Hospital, Xi'an, Shaanxi, 710100

More Information
  • Received Date: February 17, 2020
  • Available Online: August 27, 2020
    Graphical Abstract
    • Abstract
  • Objective To explore effect of roxithromycin combined with N-acetylcysteine in treatment of chronic obstructive pulmonary disease patients complicating with pulmonary interstitial fibrosis(COPD-PIF)and its influence on pulmonary function. Methods A total of 96 COPD-PIF patients with treatment were enrolled, and were divided into two groups according to random number table method, with 48 cases in each group. The control group was treated with roxithromycin, while experimental group was additionally treated with N-acetylcysteine on basis of control group. All of them were continuously treated for 3 months. The efficacy rate of treatment, changes of lung function indexes and serum inflammatory indexes before and after treatment, occurrence of adverse reactions and quality of life scores were compared between the two groups. Results Out of the 96 patients, there were 92 cases accomplished the experiment, including 47 cases in experimental group and 45 cases in control group. There was no significant difference in efficacy rate of treatment between experimental group and control group(93.62% vs. 84.44%, P>0.05). After treatment, ratios of vital capacity(VC), forced expiratory volume in 1 second(FEV1), and carbon monoxide diffusion capacity(DISO)to predicted value in experimental group were significantly higher than those in control group - (P<0.05). After treatment, levels of interleukin-6(IL-6), interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in experimental group were lower than those in control group(P<0.05). There were no significant differences in incidence of adverse reactions and quality of life scores after treatment between the two groups(P>0.05). Conclusion Roxithromycin combined with N-acetylcysteine has significant efficacy in treating COPD-PIF patients, which can effectively improve lung function indexes and serum inflammatory factors, and has no increase in adverse reactions.
    • FullText(HTML)
    • References (21)
  • 张飔雪. 噻托溴铵联合沙美特罗替卡松对重度COPD患者肺功能、氧化应激状态及脂质水平的影响分析[J]. 中国医学前沿杂志: 电子版, 2017, 9(10): 132-136.
    杜俊凤, 任少达, 迟玉敏, 等. 慢性阻塞性肺疾病并发侵袭性肺曲霉菌病的临床特征和危险因素分析[J]. 中国医学前沿杂志: 电子版, 2017, 9(7): 132-135.
    矫翠婷, 邵玉霞. 保肺康汤对COPD合并肺间质纤维化患者血气、肺功能指标与胸部影像学的影响[J]. 四川中医, 2017, 35(11): 77-80.
    张松, 黄茂. 罗红霉素抑制COPD大鼠炎性介质释放对糖皮质激素抵抗的影响[J]. 实用药物与临床, 2018, 21(6): 611-614.
    甘庆, 王进, 曾兴虹. NAC联合NIPV对AECOPD合并Ⅱ型呼吸衰竭患者肺功能、血气参数和血清SOD、sICAM-1、HMGB-1、sTREM-1水平的影响[J]. 中国医学前沿杂志: 电子版, 2019, 11(8): 122-126.
    中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J]. 中华内科杂志, 2007, 46(3): 254-261.
    Cella D F, Bonomi A E, Lloyd S R, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung(FACT-L)quality of life instrument[J]. Lung Cancer, 1995, 12(3): 199-220.
    Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial[J]. Thorax, 2017, 72(5): 415-423.
    杨晶晶, 聂秀红, 魏兵, 等. COPD患者体重差异对人体成分、运动耐力及预后影响的研究[J]. 中国医学前沿杂志: 电子版, 2018, 10(6): 173-178.
    刘晓明, 李芮. 李芮从肾虚血瘀论治慢性阻塞性肺疾病合并肺间质纤维化的经验[J]. 中医药导报, 2017, 23(15): 116-117.
    李军华, 刘春燕, 喻小菊, 等. 肺功能锻炼对慢性阻塞性肺疾病患者肌肉功能及肺通气功能的影响分析[J]. 中国医学前沿杂志: 电子版, 2017, 9(6): 68-73.
    黄有环, 王瑞光, 李志良. 噻托溴铵联合无创机械通气对重度稳定期慢性阻塞性肺疾病患者肺功能及血清炎性因子的影响[J]. 中国医学前沿杂志: 电子版, 2017, 9(6): 74-77.
    邹琴, 王博龙. 长期小剂量罗红霉素对稳定期慢性阻塞性肺疾病疗效作用的Meta分析[J]. 中国抗生素杂志, 2018, 43(10): 156-164.
    孙丹丹, 徐挺挺, 周王锋, 等. 罗红霉素对人支气管上皮细胞糖皮质激素抵抗的作用及其机制[J]. 中华医学杂志, 2017, 97(28): 2215-2219.
    黄玉芳, 石惠. N-乙酰半胱氨酸联合布地奈德/福莫特罗治疗慢性阻塞性肺疾病急性加重的临床效果[J]. 中国医学前沿杂志: 电子版, 2016, 8(8): 68-71.
    陈珊珊, 李华敏, 陈建寿, 等. 大剂量N-乙酰半胱氨酸联合糖皮质激素治疗慢性阻塞性肺疾病并肺间质纤维化的临床疗效[J]. 实用心脑肺血管病杂志, 2017, 25(3): 97-100.
    胡贵芳, 王治国, 樊莉莉. 乙酰半胱氨酸泡滕片辅助治疗稳定期COPD患者心肺功能、气道重塑的影响[J]. 海南医学院学报, 2017, 23(9): 1195-1198

    , 1202.
    付伟, 辛丽云, 陈乾华. 乙酰半胱氨酸溶液雾化吸入对COPD患者免疫功能及肺功能的影响[J]. 实用药物与临床, 2019, 22(6): 597-600.
    刘勇. N-乙酰半胱氨酸对老年慢性阻塞性肺疾病患者免疫功能及细胞因子的影响[J]. 现代中西医结合杂志, 2017, 26(17): 1880-1882.
    王永仓, 孟婷, 孙莹, 等. 小剂量罗红霉素联合N-乙酰半胱氨酸对支气管扩张合并慢性肺源性心脏病疗效观察[J]. 临床肺科杂志, 2017, 22(12): 2315-2318

    , 2320.
    谷志彬, 房莉颖. 无创呼吸机治疗特发性肺间质纤维化合并呼吸衰竭患者的临床效果[J]. 实用临床医药杂志, 2019, 23(5): 63-65.
    • Related Articles

  • Related Articles

    [1]FANG Zhiqin, LIANG Huiqing, ZHANG Pengxiang, ZHAO Kun, MA Yiping, WANG Yaling, LI Fangjiang, LI Jun, LI Pingping. Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 70-75. DOI: 10.7619/jcmp.20241838
    [2]SONG Jin. Clinical effect of butylphthalide injection combined with rosuvastatin calcium tablets in the treatment of acute progressive cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2019, 23(17): 45-47, 51. DOI: 10.7619/jcmp.201917013
    [3]YE Lei, WEN Li. Effect of rosuvastatin on vascular endothelial function, cardiac function and hemodynamics in patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2018, (1): 18-20. DOI: 10.7619/jcmp.201801006
    [4]XIAO Ru'nan. Efficacy of nursing intervention in the treatment of amlodipine and atorvastatin calcium tablet for patients with hypertension combined with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2017, (4): 1-3,7. DOI: 10.7619/jcmp.201704001
    [5]JU Yanling, ZANG Xuelian, ZHAO Xu. Effect of amlodipine atorvastatin calcium tablet on IMT, PV, TNF, CRP, and blood lipid level of coronary heart disease and high blood pressure patients complicated with carotid atherosclerosis[J]. Journal of Clinical Medicine in Practice, 2017, (1): 14-18. DOI: 10.7619/jcmp.201701004
    [6]LIU Juan, ZHANG Bo, ZHANG Xiaoli, TANG Lingzhi. Influence of amlodipine combined with rosuvastatin calcium on CRP and D-dimer in elderly patients with acute cerebral infarction complicated with hypertension[J]. Journal of Clinical Medicine in Practice, 2016, (23): 9-12. DOI: 10.7619/jcmp.201623003
    [7]LIANG Tao, JIANG Junsong. Effect comparison between rosuvastatin and atorvastatin on the myocardial damage and levels of inflammatory factors in patients with unstable angina pectoris in perioperative period of percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2016, (3): 18-20,24. DOI: 10.7619/jcmp.201603006
    [8]TANG Bo. Clinical effect of rosuvastatin versus atorvastatin in treatment of coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2015, (Z1): 168-169.
    [9]WANG Xin, ZHAO Donghui. Influence of different doses of rosuvastatin on serum hs-CRP and PAPP-A level after stents implantation in patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2014, (19): 1-3. DOI: 10.7619/jcmp.201419001
    [10]XU Weidong, MIN Zhaohan. Effects of rosuvastatin on the levels of blood glucose, blood lipid and hypersensitive C-reactive protein in patients with hypertension[J]. Journal of Clinical Medicine in Practice, 2013, (7): 27-28,32. DOI: 10.7619/jcmp.201307008

  • Cited by

    Periodical cited type(4)

    1. 胡婷婷，曹成瑛，赵文兴，王生元，何莹. 基于冠状动脉CT血管造影的血流储备分数对高原高海拔环境下冠心病的诊断价值. 现代生物医学进展. 2024(11): 2173-2176+2191 .
    2. 徐磊，尹浩，黄飞，赵渊，和旭，何永福. 分析亚高原地区人群发生冠状动脉性心脏病的影响因素. 大医生. 2024(16): 99-102 .
    3. 赵志伟，邢志政，孙晨格，崔梁瑜，任聪，李玉坤，罗玮伯，吕诚，韩学杰，刘大胜. 高原地区冠心病的中医辨证与证素分布规律研究. 中医药导报. 2024(10): 96-102 .
    4. 刘斌，张敏，李显刚，林仁华，杨洁，张亮，何跃，王显昆，潘娅楠. 边疆少数民族彝族人群rs1333049单核苷酸多态性与冠心病的联系. 检验医学与临床. 2023(02): 160-165 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (547) PDF downloads (12) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return